On July 29, Bruker rose 5.18% in regular trading, trading at $63.26/share, with turnover of $96.36 million. The stock benefited from both a sector-wide rally in life sciences tools and a recent analyst upgrade.

BofA Securities recently raised its price target on Bruker to $70 from $65, maintaining an overweight rating. This marks the second consecutive upward revision by the firm, which had previously lifted its target from $49 to $65 in early June. The broader Life Sciences Tools & Services sector saw significant strength on the day, with Repligen surging 13.93%, IQVIA climbing 13.92%, Thermo Fisher Scientific gaining 2.28%, and Danaher rising 1.88%.

Bruker is scheduled to report its next quarterly earnings on August 4 before market open, with consensus EPS estimates at $0.38. The company previously guided full-year adjusted EPS of $2.10–$2.15 and revenue of $3.57–$3.60 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)